Cipla Q3 preview: Up to 7% YoY uptick seen in revenue. Margins to fall on a YoY and sequential basis

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differing views on its performance, citing challenges like Lanreotide supply disruptions and market share fluctuations. Key factors include drug updates and the timeline for launches. The company will announce earnings on January 28, 2025.